Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744945 | 0.94 | DUT (0.36) | DUTSMN1; SMN2LMNAALDH1A1PKM | |
| SCHEMBL4511606 | 0.82 | HTR7 (0.51) | DUTHTR7MCL1MAPT | |
| SCHEMBL1744651 | 0.80 | DUT (0.41) | DUTHTR7MCL1DGAT1 | |
| SCHEMBL1464500 | 0.80 | GLS (0.38) | DUTSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL31487744 | 0.77 | DUT (0.41) | DUTLMNAALDH1A1DGAT1KDM4E | |
| SCHEMBL1746128 | 0.75 | GLS (0.34) | ALDH1A1 | |
| SCHEMBL9091990 | 0.73 | HTR2A (0.48) | DUTHTR7 | |
| SCHEMBL31129868 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAALDH1A1MAPTNPC1 | |
| SCHEMBL4001230 | 0.72 | DUT (0.45) | DUTHTR7MCL1DGAT1 | |
| SCHEMBL9092781 | 0.72 | HTR7 (0.49) | DUTHTR7MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2385939-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8041551-B1 | Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components | THE MATHWORKS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | DUT 1451/4885SMN1; SMN2 2776/4885LMNA 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.